Showing 1 - 8 of 8
We review the recent literature on financing biomedical innovation, with a specific focus on the drug development process and how it may be enhanced to improve outcomes. We begin by laying out stylized facts about the structure of the drug development process and its associated costs and risks,...
Persistent link: https://www.econbiz.de/10014242491
The interaction between product market competition, R&D investment, and the financing choices of R&D-intensive firms on the development of innovative products is only partially understood. To motivate empirical hypotheses about this interaction, we develop a model which predicts that as...
Persistent link: https://www.econbiz.de/10013249274
Persistent link: https://www.econbiz.de/10010490808
How does competition affect innovation and how it is financed in R&D-intensive firms? We study the interaction between competition, R&D investments, and the financing choices of such firms using data on biopharmaceutical firms. To motivate the empirical hypotheses, we develop a model for such...
Persistent link: https://www.econbiz.de/10013029032
How does competition affect innovation and how it is financed in R&D-intensive firms? We study the interaction between competition, R&D investments, and the financing choices of such firms using data on biopharmaceutical firms. To motivate the empirical hypotheses, we develop a model for such...
Persistent link: https://www.econbiz.de/10012457763
What is the interaction between competition, R&D investments, and the financing choices of R&D-intensive firms? Motivated by existing theories, we hypothesize that as competition increases, R&D-intensive firms will: (1) increase R&D investment relative to assets-in-place that support existing...
Persistent link: https://www.econbiz.de/10012937531
Persistent link: https://www.econbiz.de/10013367043
Persistent link: https://www.econbiz.de/10013461130